Chairs: Reuven Ferziger, MD; Ronald Manderscheid, PhD
Historically the pipeline between discovering potential new treatments and making new treatments available to patients has benefited from robust scientific interaction between industry, academia and government. In recent years, these interactions have become increasingly complex. Many observers have related the dampening of industry-academia collaboration to the decline in the number of innovative new drugs developed annually. An important factor affecting scientific collaboration has been greatly heightened concern about the ethical and legal standards observed in these relationships. Over the last decade, psychiatric diseases have been at once one of the slowest areas of drug innovation and one of the most frequently identified areas of ethical concern and legal action. A growing number of initiatives are providing frameworks to stimulate industry-academia collaboration while maintaining legal and ethical boundaries. But it has been much easier to do this in “pre-competitive space,” at the more upstream, basic research end of the pipeline, than downstream, at the clinical research and patient care end of drug development.
In Part 1 of this year’s ISCTM Policy Forum, leaders from academia, industry, government and journalism will describe the problems constraining academia-industry collaboration and paths bring pursued to optimize collaboration. In Part 2, the speaker panel and the audience will be presented with cases that both encourage and challenge opportunities for academia-industry collaboration. The cases will focus on downstream research on psychiatric diseases and treatments. The case discussions will be moderated to encourage audience participation.
The Forum will begin with keynote remarks by Jeffrey Lieberman, President of the American Psychiatric Association. Case discussions will be moderated by Howard Goldman (Editor, Psychiatric Services). Invited speakers include Richard Frank (HHS Deputy Secretary Nominee), Freda Lewis Hall (Chief Medical Officer, Pfizer).
REGISTER FOR THE ISCTM POLICY FORUM
Registration for the Forum Only session is complimentary.